Cognitive enhancement blend: PE-22-28 + Pinealon + Semax + Selank
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Beginner | 1 mg | 5 days on, 2 off | — |
| Intermediate | 2 mg | 5 days on, 2 off | — |
| Advanced | 3 mg | 5 days on, 2 off | — |
| Maximum | 5 mg | 5 days on, 2 off | — |
Blend Dosing Approach
IllumiNeuro is formulated as a **fixed-ratio blend** with pre-determined concentrations: PE-22-28 (10mg), Pinealon (10mg), Semax (20mg), and Selank (8mg). This **pre-combined format** eliminates the complexity of measuring multiple individual peptides and ensures consistent ratios optimized for synergistic effects. Since the peptides are already combined, dosing is **volume-based** rather than concentration-based, simplifying administration protocols. The blend can typically be administered via **subcutaneous or intranasal routes**, with intranasal delivery potentially offering faster onset due to direct nose-to-brain transport pathways utilized by Semax and Selank. Given the relatively short half-lives of the component peptides (20-30 minutes for most), **multiple daily dosing** may be necessary to maintain therapeutic levels, though the neuroplastic effects may persist beyond the peptides' direct presence. The fixed ratios are designed to balance immediate cognitive effects with longer-term neuroplastic benefits.
Per-Component Breakdown
Synergy Rationale
IllumiNeuro combines four peptides with complementary mechanisms targeting **cognitive enhancement** through distinct yet interconnected pathways. PE-22-28 and Semax both upregulate **brain-derived neurotrophic factor (BDNF)**, creating synergistic neuroplasticity effects that may enhance learning and memory formation. While Semax primarily targets **dopaminergic pathways** for focus and attention, Selank modulates **GABAergic and serotonergic systems** to reduce anxiety without cognitive impairment, creating an optimal mental state for enhanced performance. Pinealon contributes through **DNA repair and cellular longevity** mechanisms, potentially supporting the long-term health of neurons enhanced by the other peptides. This combination addresses multiple aspects of cognitive function: **neurogenesis** (PE-22-28), **neurotransmitter optimization** (Semax, Selank), **stress resilience** (Selank), and **cellular maintenance** (Pinealon). The rationale centers on creating a comprehensive cognitive enhancement profile that simultaneously promotes new neural growth, optimizes existing neural networks, and maintains cellular health for sustained cognitive benefits.
Combined Mechanism
The IllumiNeuro blend creates a **multi-pathway approach** to cognitive enhancement through overlapping and complementary mechanisms. Both PE-22-28 and Semax activate **BDNF signaling cascades**, potentially creating amplified effects on **neuroplasticity and synaptic strength**. The shared activation of **MAPK/ERK and PI3K/Akt pathways** by these peptides may result in enhanced protein synthesis and gene expression changes supporting neuronal function. Semax's **dopaminergic enhancement** provides the neurochemical foundation for improved focus and working memory, while Selank's **GABAergic modulation** creates an optimal anxiety-free state for cognitive performance. The **anti-inflammatory properties** shared by multiple components (PE-22-28, Semax, and Selank) may create a synergistic neuroprotective environment by reducing neuroinflammation and promoting **M2 microglial phenotypes**. Pinealon's **epigenetic modulation** and **DNA repair enhancement** may support the cellular infrastructure needed for the neuroplastic changes promoted by the other peptides. The combined **neurotrophic factor upregulation**, **neurotransmitter optimization**, and **cellular maintenance** create a comprehensive approach that addresses immediate cognitive performance while supporting long-term brain health through multiple interconnected signaling networks.
Research Context
Direct research on this specific **four-peptide combination** is extremely limited in peer-reviewed literature, as most studies focus on individual peptide effects rather than complex blends. However, research on **multi-modal nootropic approaches** suggests potential benefits of combining peptides with complementary mechanisms targeting different aspects of cognitive function. Studies on **BDNF-enhancing compounds** indicate that multiple pathways of neurotrophin upregulation may create additive effects on neuroplasticity. The combination of **anxiolytic and cognitive-enhancing** peptides (Selank + Semax) has some precedent in Russian research, though comprehensive interaction studies are lacking. **Peptide bioregulator research** suggests that combining compounds with different temporal profiles and mechanisms may provide more comprehensive benefits than single-agent approaches. Current **knowledge gaps** include specific drug-drug interactions, optimal dosing ratios, and long-term safety profiles of combined administration. This represents an area where empirical research significantly outpaces controlled clinical studies, emphasizing the investigational nature of such combinations.
Research Use Only: All compounds discussed on this page are intended for laboratory research purposes only. Not for human consumption. All research should be conducted in compliance with institutional guidelines and applicable regulations. Consult qualified healthcare professionals before making any decisions regarding compound research or use.
IllumiNeuro
Quick Reference
- Default Dose
- 1 mg
- Frequency
- 5 days on, 2 off
- Timing
- AM
- Dilution
- 2 ml
For Practitioners
Interested in offering research-grade compounds through your practice? Learn about our affiliate program for qualified practitioners.
Find a ProviderPractitioner Information